Literature DB >> 25639994

First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial.

Vinod H Srihari1, Cenk Tek1, Suat Kucukgoncu1, Vivek H Phutane1, Nicholas J K Breitborde1, Jessica Pollard1, Banu Ozkan1, John Saksa1, Barbara C Walsh1, Scott W Woods1.   

Abstract

OBJECTIVE: This study sought to determine the effectiveness of a comprehensive first-episode service, the clinic for Specialized Treatment Early in Psychosis (STEP), in an urban U.S. community mental health center by comparing it with usual treatment.
METHODS: This pragmatic randomized controlled trial enrolled 120 patients with first-episode psychosis within five years of illness onset and 12 weeks of antipsychotic exposure. Referrals were mostly from inpatient psychiatric units, and enrollees were randomly allocated to STEP or usual treatment. Main outcomes included hospital utilization (primary); the ability to work or attend age-appropriate schooling-or to actively seek these opportunities (vocational engagement); and general functioning. Analysis was by modified intent to treat (excluding only three who withdrew consent) for hospitalization; for other outcomes, only data for completers were analyzed.
RESULTS: After one year, STEP participants had less inpatient utilization compared with those in usual treatment: no psychiatric hospitalizations, 77% versus 56% (risk ratio [RR]=1.38, 95% confidence interval [CI]=1.08-1.58); mean hospitalizations, .33±.70 versus .68±.92 (p=.02); and mean bed-days, 5.34±13.53 versus 11.51±15.04 (p=.05). For every five patients allocated to STEP versus usual treatment, one additional patient avoided hospitalization over the first year (number needed to treat=5; CI=2.7-26.5). STEP participants also demonstrated better vocational engagement (91.7% versus 66.7%; RR=1.40, CI=1.18-1.48) and showed salutary trends in global functioning measures.
CONCLUSIONS: This trial demonstrated the feasibility and effectiveness of a U.S. public-sector model of early intervention for psychotic illnesses. Such services can also support translational research and are a relevant model for other serious mental illnesses.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25639994      PMCID: PMC4490067          DOI: 10.1176/appi.ps.201400236

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  32 in total

Review 1.  Pragmatic randomised controlled trials in psychiatry.

Authors:  M Hotopf; R Churchill; G Lewis
Journal:  Br J Psychiatry       Date:  1999-09       Impact factor: 9.319

2.  Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

Authors:  Delbert G Robinson; Margaret G Woerner; Marjorie McMeniman; Alan Mendelowitz; Robert M Bilder
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

3.  The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients.

Authors:  M Birchwood; J Smith; R Cochrane; S Wetton; S Copestake
Journal:  Br J Psychiatry       Date:  1990-12       Impact factor: 9.319

4.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

5.  Risk for suicide in schizophrenia and other psychotic and nonpsychotic disorders.

Authors:  J F Westermeyer; M Harrow; J T Marengo
Journal:  J Nerv Ment Dis       Date:  1991-05       Impact factor: 2.254

6.  Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory.

Authors:  D O Perkins; J Leserman; L F Jarskog; K Graham; J Kazmer; J A Lieberman
Journal:  Schizophr Res       Date:  2000-07-07       Impact factor: 4.939

7.  The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome.

Authors:  D W Heinrichs; T E Hanlon; W T Carpenter
Journal:  Schizophr Bull       Date:  1984       Impact factor: 9.306

8.  Assessing depression in schizophrenia: the Calgary Depression Scale.

Authors:  D Addington; J Addington; E Maticka-Tyndale
Journal:  Br J Psychiatry Suppl       Date:  1993-12

9.  Global assessment of functioning. A modified scale.

Authors:  R C Hall
Journal:  Psychosomatics       Date:  1995 May-Jun       Impact factor: 2.386

10.  The UK national evaluation of the development and impact of Early Intervention Services (the National EDEN studies): study rationale, design and baseline characteristics.

Authors:  Max Birchwood; Helen Lester; Linda McCarthy; Peter Jones; David Fowler; Tim Amos; Nick Freemantle; Vimal Sharma; Anna Lavis; Swaran Singh; Max Marshall
Journal:  Early Interv Psychiatry       Date:  2013-01-24       Impact factor: 2.732

View more
  36 in total

1.  ThriveNYC: Delivering on Mental Health.

Authors:  Gary Belkin; Chirlane McCray
Journal:  Am J Public Health       Date:  2019-06       Impact factor: 9.308

2.  Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program.

Authors:  John M Kane; Delbert G Robinson; Nina R Schooler; Kim T Mueser; David L Penn; Robert A Rosenheck; Jean Addington; Mary F Brunette; Christoph U Correll; Sue E Estroff; Patricia Marcy; James Robinson; Piper S Meyer-Kalos; Jennifer D Gottlieb; Shirley M Glynn; David W Lynde; Ronny Pipes; Benji T Kurian; Alexander L Miller; Susan T Azrin; Amy B Goldstein; Joanne B Severe; Haiqun Lin; Kyaw J Sint; Majnu John; Robert K Heinssen
Journal:  Am J Psychiatry       Date:  2015-10-20       Impact factor: 18.112

3.  Accounting for group differences in study retention in a randomized trial of specialized treatment for first episode psychosis.

Authors:  Kyaw Sint; Robert Rosenheck; Delbert G Robinson; Nina R Schooler; Patricia Marcy; John M Kane; Kim T Mueser; Haiqun Lin
Journal:  Schizophr Res       Date:  2017-08-25       Impact factor: 4.939

4.  Care Pathways Before First Diagnosis of a Psychotic Disorder in Adolescents and Young Adults.

Authors:  Gregory E Simon; Christine Stewart; Enid M Hunkeler; Bobbi Jo Yarborough; Frances Lynch; Karen J Coleman; Arne Beck; Belinda H Operskalski; Robert B Penfold; David S Carrell
Journal:  Am J Psychiatry       Date:  2018-01-24       Impact factor: 18.112

5.  Lessons Learned in Clinical Research Recruitment of Immigrants and Minority Group Members with First-Episode Psychosis.

Authors:  Mercedes Hernandez; Richard Franco; Alex Kopelowicz; Maria Y Hernandez; Yesenia Mejia; Concepción Barrio; Steven Regeser López
Journal:  J Immigr Minor Health       Date:  2019-02

6.  Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention.

Authors:  Delbert G Robinson; Nina R Schooler; Christoph U Correll; Majnu John; Benji T Kurian; Patricia Marcy; Alexander L Miller; Ronny Pipes; Madhukar H Trivedi; John M Kane
Journal:  Am J Psychiatry       Date:  2017-09-15       Impact factor: 18.112

7.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

8.  Analysis of Early Intervention Services on Adult Judicial Outcomes.

Authors:  Jessica M Pollard; Maria Ferrara; I-Hsin Lin; Suat Kucukgoncu; Tobias Wasser; Fangyong Li; Vinod H Srihari
Journal:  JAMA Psychiatry       Date:  2020-08-01       Impact factor: 21.596

9.  Duration of the psychosis prodrome.

Authors:  Albert R Powers; Jean Addington; Diana O Perkins; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Daniel H Mathalon; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan; Scott W Woods
Journal:  Schizophr Res       Date:  2019-12-02       Impact factor: 4.939

10.  Predictors of Hospitalization of Individuals With First-Episode Psychosis: Data From a 2-Year Follow-Up of the RAISE-ETP.

Authors:  Delbert G Robinson; Nina R Schooler; Robert A Rosenheck; Haiqun Lin; Kyaw J Sint; Patricia Marcy; John M Kane
Journal:  Psychiatr Serv       Date:  2019-05-14       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.